TQ-1017

TQ-1017 is an abuse-deterrent, once-daily extended-release formulation of the analgesic tramadol, developed by TheraQuest Biosciences. It utilizes a proprietary 'Secure-Release' system designed to provide sustained pain relief while incorporating physical and chemical barriers to prevent misuse, such as resistance to crushing for inhalation and difficulty in extracting the active ingredient with common solvents. Tramadol, the active component, exerts its effects through a dual mechanism: acting as a weak agonist at the mu-opioid receptor and inhibiting the reuptake of serotonin and norepinephrine. TQ-1017 was granted FDA Orphan Drug Designation for the treatment of HIV-related neuropathic pain and postherpetic neuralgia, though clinical development has since been discontinued.